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Covalent immobilisation of antibodies in
Teﬂon-FEP microﬂuidic devices for the sensitive
quantiﬁcation of clinically relevant protein
biomarkers†
Jeremy Pivetal,a Filipa M. Pereira,b Ana I. Barbosa,b,c Ana P. Castanheira,b
Nuno M. Reis*b,c,d and Alexander D. Edwards*a,b
This study reports for the ﬁrst time the sensitive colorimetric and ﬂuorescence detection of clinically rele-
vant protein biomarkers by sandwich immunoassays using the covalent immobilisation of antibodies onto
the ﬂuoropolymer surface inside Teﬂon®-FEP microﬂuidic devices. Teﬂon®-FEP has outstanding optical
transparency ideal for high-sensitivity colorimetric and ﬂuorescence bioassays, however this thermoplas-
tic is regarded as chemically inert and very hydrophobic. Covalent immobilisation can oﬀer beneﬁts over
passive adsorption to plastic surfaces by allowing better control over antibody density, orientation and
analyte binding capacity, and so we tested a range of diﬀerent and novel covalent immobilisation strat-
egies. We ﬁrst functionalised the inner surface of a 10-bore, 200 µm internal diameter FEP microcapillary
ﬁlm with high-molecular weight polyvinyl alcohol (PVOH) without changing the outstanding optical trans-
parency of the device delivered by the matched refractive index of FEP and water. Glutaraldehyde immo-
bilisation was compared with the use of photoactivated linkers and NHS-ester crosslinkers for covalently
immobilising capture antibodies onto PVOH. Three clinically relevant sandwich ELISAs were tested against
the cytokine IL-1β, the myocardial infarct marker cardiac troponin I (cTnI), and the chronic heart failure
marker brain natriuretic peptide (BNP). Overall, glutaraldehyde immobilisation was eﬀective for BNP
assays, but yielded unacceptable background for IL-1β and cTnI assays caused by direct binding of the
biotinylated detection antibody to the modiﬁed PVOH surface. We found NHS-ester groups reacted with
APTES-treated PVOH coated ﬂuoropolymers. This facilitated a novel method for capture antibody immo-
bilisation onto ﬂuoropolymer devices using a bifunctional NHS-maleimide crosslinker. The density of co-
valently immobilised capture antibodies achieved using PVOH/APTES/NHS/maleimide approached levels
seen with passive adsorption, and sensitive and quantitative assay performance was achieved using this
method. Overall, the PVOH coating provided an excellent surface for controlled covalent antibody immo-
bilisation onto Teﬂon®-FEP for performing high-sensitivity immunoassays.
Introduction
Antibody immobilisation is a key step in heterogeneous
immunoassays requiring the eﬀective irreversible binding of
antibody molecules onto a solid sensor surface, whilst retain-
ing the antigen binding capacity and preventing non-specific
binding. Although antibodies can be passively adsorbed onto
many surfaces, multiple studies in a range of analytical
systems have indicated that the covalent immobilisation of
antibodies oﬀers performance advantages over passive adsorp-
tion, because an antibody can lose structure and the antigen
binding site can be blocked or inactivated when passively
adsorbed onto polymer devices and plastic microplates.1–4
Covalent methods can oﬀer control of the antibody surface
density, and improve orientation and activity,5,6 all essential
for maximising device performance and delivering high-
sensitivity miniaturised immunoassays using amplified detec-
tion methods such as enzyme-linked immunosorbent assays
(ELISA).
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Microfluidic immunoassay devices can be produced from a
diverse range of materials each with distinct advantages and
drawbacks. Fluoropolymers represent one unusual class with
several unique properties that are very distinct from glass or
poly(dimethylsiloxane) – PDMS – the most conventional sub-
strate for microfluidic device fabrication.7 The potential of
exploiting the unique optical and dielectrical properties of
fluoropolymers was initially recognised in the context of bio-
sensor development, for example in early studies evaluating if
their surface properties could be compatible with cell neural
growth.8 Subsequent studies established specialised micro-
fabrication methods to overcome material properties that
make microchannel formation more challenging.9 The com-
bined flexibility plus chemical inertness of fluoropolymer
films was exploited for the production of valves and pumps in
glass microfluidic devices.10 Similarly, the high melting point
Teflon film was exploited to make heat-proof components of a
robust PCR device.11 However, the high melting temperature
also makes microchannel device fabrication challenging, so
specialised moulding techniques were developed to pattern
Teflon with high resolution to make microfluidic chips.12 One
unique material property of fluoropolymers is their unusually
low refractive index that can closely match that of water, which
means that no refraction occurs at the interface between the
device and aqueous samples or reagent solutions, reducing
optical distortion that can lead to a high background, signal
crosstalk or loss of signal for any optical detection method.13
Refractive index matching has also been exploited to produce
optically unusual colloidal fluoroelastomer nanoparticles.14
Likewise, the unique refractive index of fluoropolymers allows
label-free protein binding to be detected at the reflective
surface of an amorphous fluoropolymer substrate.15 Refractive
index matching has recently been shown to enhance the
optical detection sensitivity for more conventional micro-
systems made from silica capillaries or packed glass beads in
plastic channels.16 However, unless the unusually low refrac-
tive index of fluoropolymers is exploited in device fabrication,
the refractive index of the substrate solution must be signifi-
cantly increased to match that of the device for example by
addition of glycerol or sugars.
Our research group recently reported high-sensitivity colori-
metric and fluorescence ELISA using Teflon®-FEP microfluidic
devices fabricated from a 10-bore microcapillary film (MCF), a
low-cost continuously melt-extruded microfluidic material
made from the fluoropolymer fluorinated ethylene propylene
(FEP). Using passive adsorption to coat the FEP devices we
developed simple yet highly eﬀective microfluidic immuno-
assay devices,13 that measured cancer and inflammatory bio-
markers at picomolar to femtomolar concentrations, read
using a flatbed scanner17 or a smartphone.18 When optimised
we achieved a very high analytical sensitivity measurement
(LoD 2–15 pg mL−1 i.e. 35 and 713 fM).19 However, the poten-
tial for improving the analytical performance further by using
covalent capture antibody immobilisation motivated us to try
to develop an eﬀective bioconjugation strategy for fluoropoly-
mer microfluidic devices.
The inert nature of fluoropolymers makes surface modifi-
cation and antibody immobilisation non-trivial compared to
conventional microfluidic devices where multiple surface
modification protocols have already been optimised (e.g. glass
or PDMS). Indeed, the covalent immobilisation of antibodies
in FEP microchannels has not previously been reported. The
covalent immobilisation of other proteins onto fluoropolymers
has been reported. Functional enzymes have been successfully
immobilised onto fluoropolymer supports.20–23 The surface
ion treatment of fluoropolymer films allowed patterned immo-
bilisation of poly(acrylic acid) onto FEP films by introducing
functional groups for bioconjugation.24 In other microfluidic
devices made from other materials a broad spectrum of
crosslinking chemistries have been explored,25 including
indirect immobilisation via a surface polymer coating to intro-
duce multiple reactive functional groups thereby increasing
the eﬀective antibody density and/or orientation.26,27 One ver-
satile polymer used for the surface modification of a range of
polymer materials is polyvinyl alcohol (PVOH).28
Glutaraldehyde crosslinked PVOH has been used to perma-
nently coat microcapillaries for capillary electrophoresis with a
protocol reported to exhibit low non-specific protein
binding.29 Solid phase immunoassay supports have been cast
from glutaraldehyde crosslinked PVOH, illustrating that anti-
bodies can be immobilised eﬀectively onto glutaraldehyde
treated PVOH.30
Here we investigated for the first time the sensitive quanti-
tation of clinically relevant protein biomarkers in FEP micro-
capillaries with covalently immobilised capture antibodies,
which involved carrying out sandwich ELISA in MCF devices
with antibodies immobilised covalently using a variety of
crosslinking chemistries. To produce a suitable surface for
covalent antibody immobilisation to the unreactive and hydro-
phobic FEP microcapillaries, the inner surface of the micro-
capillaries was firstly coated with a layer of PVOH. A range of
crosslinking chemistries were then explored in order to co-
valently immobilize antibodies onto the PVOH layer. We
started with the versatile homobifunctional dialdehyde cross-
linker glutaraldehyde which has been used for protein immo-
bilisation for decades, then explored if photoactivated cross-
linkers could react eﬀectively with PVOH, and finally explored
NHS-ester immobilisation after the introduction of reactive
free amines onto a PVOH coating using (3-aminopropyl)
triethoxysilane (APTES). Our aim in this study was to identify
new antibody immobilisation methods for fluoropolymer
immunoassay devices. These methods can then in future be
fully optimised and potentially deliver improved analytical per-
formance for clinically relevant diagnostic assays.
An acceptable analytical performance for sandwich
immunoassays frequently requires diﬀerent assay conditions
for each and every analyte, antibody pair and sample type and
so in this initial screening and feasibility study we compared
the immobilisation of a capture antibody for measurement of
interleukin 1 beta (IL-1β) studied previously in hydrophobic
FEP microcapillaries19 with capture antibodies against two
important cardiac biomarkers not previously measured in
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MCF devices: the myocardial infarct marker cardiac troponin I
(cTnI), and the chronic heart failure marker brain natriuretic
peptide (BNP).
Experimental design
Materials
We used a 10-bore MCF consisting of a flat plastic ribbon con-
taining a parallel array of microcapillaries with a mean hydra-
ulic diameter of 206 ± 12.6 µm (Fig. 1) as used in previous
studies,13,17–19 manufactured by Lamina Dielectrics Ltd
(Billingshurst, West Sussex, UK) using a continuous melt-extru-
sion process from Teflon®-FEP (fluorinated ethylene propyl-
ene) (Dow, USA). The geometry of the inner surface requiring
coating and covalent antibody immobilisation (Fig. 1B) was
imaged using an SEM high resolution field emission gun
(FEG-SEM) after gold coating using a sputter coater/carbon
evaporator.
The human IL-1β antibody pair comprised clone CRM56
capture mAb and biotin-conjugated clone CRM57 detection
mAb (eBioscience, Hatfield, UK). The human cardiac troponin
I (cTnI) antibody pair comprised clone MF4 capture (HyTest,
Turku, Finland) and biotin-conjugated clone TPC110 (SDIX,
USA). The chronic heart failure marker human brain natriure-
tic peptide (BNP) antibody pair comprised clone 50E1 capture
and biotin-conjugated clone 24C5 (HyTest, Turku, Finland).
The cTnI and BNP detection antibodies were biotin conjugated
with N-hydroxysuccinimide (NHS) activated biotin using Pierce
EZ-Link® NHS-PEG4-Biotin (cat. no. 20217) following the manu-
facturer’s instructions (Fisher UK, Loughborough, UK).
Polyvinyl alcohol (MW 146 000–186 000 g mol−1; 99+%
hydrolysed; cat. no. 363065), glutaraldehyde grade I, 25% w/v
solution in H2O (cat. no. G6257), phosphate buﬀered saline
pH 7.4 (PBS, cat. no. P4417), hydrochloric acid 37% (cat. no.
258148), TRIS hydrochloride (cat. no. PHG0002), glycine (cat.
no. 410225), (3-aminopropyl)triethoxysilane (APTES) solution
≥98.0% (cat. no. 741442), streptavidin (cat. no. 85878), strepta-
vidin–alkaline phosphatase (SA-AP, cat. no. S2890), Tween®20
(cat. no. P1379), N,N-dimethylformamide anhydrous, 99.8%
(cat. no. 227056), HRP conjugated goat anti-mouse IgG (cat.
no. A4416) and SIGMAFAST™ OPD (o-phenylenediamine di-
hydrochloride) tablets (cat. no. P9187) were purchased from
Sigma Aldrich Ltd (Dorset, SP8 4XT, UK). SuperBlock blocking
buﬀer in PBS, pH 7.2 (cat. no. PN37515), high sensitivity
streptavidin-HRP (HSS-HRP, cat. no. 21130), immobilised
TCEP disulfide reducing gel (cat. no. 77712), photoreactive
biotin reagent (EZ-link® TFPA-PEG3-Biotin) (cat. no. 21303)
and NHS-maleimide (SM(PEG)24methyl-PEG-maleimide) (cat.
no. 22114) were obtained from Fisher UK (Loughborough, UK).
AttoPhos® AP Fluorescent Substrate was from Promega
(Southampton, UK). The flatbed scanner was an HP ScanJet
G4050 (Hewlett Packard, Bracknell, UK). The AttoPhos con-
verted substrate was imaged using a blue LED excitation trans-
illuminator (IO Rodeo, Pasadena, USA) and fluorescence was
imaged through a matched amber acrylic emission filter,
using a Canon S120 digital camera (Canon, London, UK).
Coating of FEP microcapillaries with PVOH
To produce a suitable surface for covalent antibody immobili-
sation to the unreactive and hydrophobic FEP microcapillaries,
the inner surface of the microcapillaries was permanently
coated with a layer of high molecular weight PVOH. This
method was adapted from a previous study that used low
molecular weight PVOH coatings covalently crosslinked using
acidic glutaraldehyde to make FEP microcapillaries hydro-
philic.31 In that previous report, glutaraldehyde crosslinking
was used to prevent the low molecular weight PVOH coating
from being removed by repetitive washing; here we utilised
higher molecular weight PVOH that was only soluble in water
at elevated temperatures, which produced a hydrophilic
coating that was not removed by repetitive washing (Fig. S1†).
For this coating, solutions of 99+% hydrolysed PVOH with MW
146 000–186 000 g mol−1 were first prepared by fully dissolving
2 g of the polymer in 100 mL of ultra-pure water heated to near
boiling with magnetic stirring. After dilution to the required
concentration in deionized water, PVOH solutions were
injected into a 1 m long fluoropolymer MCF material using a
syringe and incubated for 2 h at room temperature. The solu-
tions were then removed with a syringe and coated MCF was
washed with immunoassay wash buﬀer comprising PBS with
0.05% v/v Tween 20 (PBST). Unless otherwise indicated, the
washing steps during all MCF modification processes
described below involved 3 mL of PBST drawn through MCF
using a 20 mL syringe.
Antibody immobilization via glutaraldehyde
Glutaraldehyde solutions (25, 5 and 0.5% w/v) were prepared
with 0.5 M HCl in ultra-pure water and injected in 1 m long
strips of PVOH coated FEP MCF using a syringe. Following
30 min of incubation at 37 °C, glutaraldehyde solutions were
Fig. 1 (A) 1 meter of ﬂat ribbon ﬂuoropolymer microcapillary ﬁlm (MCF)
with capillaries ﬁlled with blue dye to visualise. (B) FEG-SEM image of
uncoated microcapillaries within MCF cut in the plane of capillaries to
show the cylindrical internal device surface to which the capture anti-
body must be immobilised. (C) Overview contrasting established direct
adsorption vs. proposed polymer-coating and covalent capture antibody
immobilisation strategies.
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removed and the MCF was washed. For antibody immobiliz-
ation, the purified monoclonal capture antibodies anti-human
IL-1β (IL-1β capAb), anti-human cardiac troponin I (cTnI
capAb) or anti-chronic heart failure marker brain natriuretic
peptide (BNP capAb) were prepared in PBS or the indicated
reaction buﬀer, injected into PVOH coated and glutaraldehyde
treated MCF using a syringe, and incubated for 2 hours at
room temperature. The strips were then washed with 1 M Tris-
HCl buﬀer (pH 8.2), blocked by incubation at room tempera-
ture for 1 hour in Tris-HCl-glycine (pH 8.2, 1 M Tris-HCl, 1 M
glycine) and further washed with PBST. The MCF inner sur-
faces were then further blocked using SuperBlock blocking
buﬀer for 2 hours at room temperature after which the MCF
was washed with PBS.
Antibody immobilisation via reactive biotin and streptavidin
For photoactivatable biotin immobilisation, 10 mg of EZ-link®
TFPA-PEG3-Biotin reagent was dissolved in 1 mL of ultrapure
water, diluted to the indicated concentration, and injected into
1 m long PVOH-modified FEP MCF and exposed to UV for
20 min using a CAMAG® UV lamp 4 with dual wavelengths
254/366 nm, 2 × 8 W at a distance of 5 cm from the strips. The
photoreactive biotin solution was then removed and the strips
were washed with PBS.
For NHS-activated biotin immobilisation, NHS-biotin solu-
tion was prepared by dissolving 1 mg of EZ-Link® NHS-PEG4-
Biotin reagent powder in 1 mL of deionized water. The solu-
tion were then injected into 1 m strips of PVOH-modified FEP
MCF that had (except where indicated) been pre-incubated for
1 h with a 10% w/v (3-aminopropyl)triethoxysilane (APTES)
solution for 2 hours. Unless otherwise indicated, all incu-
bations were at room temperature. After incubation for 1 hour,
the NHS-biotin solution was removed and the strips were
washed with PBS.
To indirectly immobilise the biotinylated capture antibody
via streptavidin, purified monoclonal anti-human cardiac tropo-
nin I (cTnI) or cytokine IL-1β capture antibodies were first
biotinylated using EZ-Link NHS-PEG4-Biotin reagent according
to the manufacturer’s instructions. Biotin coated MCF strips
produced as described above with NHS-PEG4-Biotin were incu-
bated for 1 h in a 100 µg mL−1 streptavidin solution and sub-
sequently washed with PBS. The biotinylated capture antibody
was then diluted in PBS to the indicated concentration and
aspirated into the MCF strips using a syringe, incubated for
2 h at room temperature and washed. Finally, the capillary
films were blocked for 2 hours in SuperBlock blocking buﬀer
and further washed.
Antibody immobilisation via NHS-maleimide bifunctional
crosslinker
The NHS-maleimide solution was prepared by dissolving 5 mg
of SM(PEG)24-maleimide in 1 mL of N,N-dimethylformamide
and aspirated into a 1 m PVOH-modified MCF pre-incubated
for 2 h with 10% (3-aminopropyl)triethoxysilane (APTES) solu-
tion. After 1 h of incubation, the NHS-maleimide solution was
removed and the strip was washed with PBS. Disulfide bonds
in capture antibodies were reduced using an immobilised
TCEP disulfide reducing gel kit according to the manufac-
turer’s instructions. The resulting reduced capture antibody
solution was diluted in PBS to the indicated concentration and
incubated inside NHS-maleimide activated strips for 2 hours,
followed by washing with PBS, blocking for 2 h with
SuperBlock blocking buﬀer and washing with PBS.
Quantitation of immobilised capture antibody, biotin and
streptavidin coatings
To measure the density of the capture antibody immobilised
using diﬀerent methods, a simple direct detection method was
developed, whereby test strips were incubated with HRP conju-
gated goat anti-mouse, followed by washing, incubation with
OPD substrate, and quantitation of a colorimetric signal using
a flatbed scanner as previously described for ELISA in
MCF.13,17–19
Colorimetric and fluorescent ELISA in FEP microcapillary
devices
Quantitative ELISA was conducted in MCF test strips using a
multi-syringe aspirator device and using previously reported
test protocols,13,17–19 and full details of the immunoassay proto-
cols used are provided in the ESI (ESI† methods). In some
assays, alkaline phosphatase (AP) conjugated streptavidin was
substituted for HRP-conjugated streptavidin, and the fluo-
rescent AP substrate AttoPhos was used instead of OPD. In this
case, the fluorescence signal was captured using a digital
camera and a simple fluorescence detection system compris-
ing a blue LED excitation source and an amber acrylic emis-
sion filter. Full details are provided in the ESI.†
Results and discussion
Antibody immobilisation to PVOH coated FEP using
glutaraldehyde
We studied the covalent immobilisation of three diﬀerent
capture antibodies. These were against the inflammatory cyto-
kine IL-1β studied previously,19 and for the first time we evalu-
ated capture antibodies for two important cardiac biomarkers,
cTnI and BNP. Whilst FEP-Teflon is an inert surface, PVOH
can be coated onto FEP directly from aqueous solution21 and
recently we found that incubation with PVOH solutions pro-
duced a hydrophilic surface coating to FEP microcapillaries
that could be detected by a high capillary rise of >60 mm, indi-
cating a reduction in the contact angle from the very hydro-
phobic uncoated FEP.31 As our aim was to achieve the indirect
immobilisation to fluoropolymer microdevices via polymer
coating (Fig. 1C), we initially tested the coupling of an anti-
body to PVOH via glutaraldehyde. Incubation of the PVOH-
coated FEP with acidic glutaraldehyde produced a chemically
activated surface that allowed eﬀective antibody immobilis-
ation and we could detect significant levels of immobilisation
using direct detection using anti-mouse-HRP for all three
capture antibodies (Fig. 2A–C). The density of the capture anti-
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body detected using anti-mouse-HRP was dependent on the
concentration of glutaraldehyde used to activate the PVOH
coating, the concentration of the capture antibody, and also
on the antibody clone (Fig. 2A–C). No signal was observed
without the capture antibody, indicating that the anti-mouse-
HRP was not non-specifically binding to the modified surface,
and that the signal observed reflected the immobilisation of
the capture antibody.
Although these experiments confirmed that the glutaralde-
hyde plus PVOH coating was suitable for immobilising pro-
teins, when full sandwich ELISA assays were performed in
MCF devices prepared using this method, variable levels of
increased assay background were observed (Fig. 2D–F). To
clearly visualise the diﬀerences in the assay background over a
wide dynamic range, assay data were presented on a log–log
plot. For the IL-1β assay, the background was so high at all
glutaraldehyde concentrations tested that no diﬀerence in the
signal could be detected in the presence of any concentration
of IL-1β, in contrast to the passively adsorbed capture antibody
that gave excellent quantitation and sensitive IL-1β detection
(Fig. 2D). With cTnI, the background was also very high except
at the lowest concentration of glutaraldehyde, where some
increase in the signal was evident with the addition of high
concentrations of cTnI (Fig. 2E). At this lowest (0.5% w/v) con-
centration of glutaraldehyde the capture antibody density was
far lower than with passive adsorption in uncoated FEP micro-
capillaries, and the very poor assay performance reflects both a
high background and low signal. We believe that this low
signal is at least in part due to the suboptimal capture anti-
body density. It is important to note however that assay per-
formance is not simply a product of high capture antibody
density, since antibody orientation and maintaining the struc-
tural integrity of the antibody protein is also important for
analyte capturing. Many studies of antibody immobilisation
onto diﬀerent surfaces report that lower antibody densities can
make the antibodies relax on the surface making it diﬃcult for
the antigen to bind. Conversely, a very high antibody density
can create steric hindrance, which also impairs antigen
binding.1 To fully understand antibody orientation and struc-
tural confirmation, additional analyte binding and biophysical
studies are now required.
In contrast to the IL-1β and cTnI assays, with the BNP anti-
body pair it was possible to perform sensitive and quantitative
BNP ELISA using glutaraldehyde activated PVOH to immobi-
lise the capture mAb (Fig. 2F). Although capture antibody den-
sities were significantly lower than those achieved using
passive adsorption (Fig. 2C), good assay performance was poss-
ible with both the maximal signal and background dependent
on the exact concentration of glutaraldehyde used to immobi-
lise the capture antibody (Fig. 2F). Although the assay back-
ground was higher with PVA and glutaraldehyde immobilised
BNP capture antibody than with direct adsorption, it remained
low enough for the eﬀective quantitation of BNP with an absor-
bance well below 0.01 absorbance units (Fig. 2F). A full ana-
lysis of the variable and high background seen with some –
but not all – assays when the capture antibody was immobi-
lised using glutaraldehyde identified that the direct binding of
some detection antibodies was a major problem, especially
when used at higher concentrations. A detailed analysis is
given in the ESI (Fig. S2†).
Although the immobilisation of higher levels of the capture
antibody required glutaraldehyde, with the IL-1β capture anti-
body a low level of the IgG signal was observed even without
glutaraldehyde, suggesting some passive adsorption to the
PVOH-coated fluoropolymer. In contrast, the cTnI capture
mouse IgG was undetectable without glutaraldehyde (compare
Fig. 2A and 2B). Further investigation showed that it is poss-
ible to coat FEP with both an antibody and PVOH, but to
Fig. 2 Capture antibody immobilisation onto hydrophilic PVOH coated
FEP MCF using glutaraldehyde causes a high and variable assay back-
ground. The capacity of glutaraldehyde activated PVOH coatings for the
capture antibody was assessed for a range of glutaraldehyde concen-
trations using direct detection with anti-mouse HRP and colorimetric
detection for three diﬀerent capture antibodies for detection of the
inﬂammatory cytokine IL-1β (A), and for the cardiac biomarkers cTnI (B)
and BNP (C). Colorimetric ELISA was then performed for these three
analytes using a capture antibody concentration of 80 μg mL−1 and the
indicated glutaraldehyde concentration (D–F). In all cases glutaralde-
hyde plus PVOH immobilisation was compared to the passively adsorbed
capture antibody. Note: immunoassay data are presented on a log–log
scale to allow visualisation of signal variation across a large dynamic
range (D–F), in contrast to the measurement of the capture antibody
density presented on linear plots (A–C).
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achieve a higher capture antibody density the antibody must
be adsorbed before PVOH coating (Fig. S3†).
PVOH coated FEP microcapillaries are reactive with
photoreactive and NHS-ester biotin, allowing antibody
immobilisation via streptavidin
Although free alcohols on the hydrophilic PVOH coating are
less reactive than the amines, carbonyls, sulfhydryls or other
groups that are usually preferred for bioconjugation, we used
reactive biotin to explore if the various standard bioconjuga-
tion and immobilisation chemistries could react with the
PVOH coating. Without glutaraldehyde crosslinking, low mole-
cular weight PVOH was removed by washing, and so we found
it necessary to use higher molecular weight PVOH which
remained coated onto the FEP microcapillaries even after
extensive washing (Fig. S1†). A photoreactive biotin was tested
since light activation generates highly reactive groups that will
react with a broad range of surfaces. We also explored if NHS-
ester activated biotin could be eﬀectively reacted with PVOH
after pre-treatment with APTES to introduce free amines. We
used biotin so that we could rapidly evaluate immobilisation
using streptavidin–enzyme conjugates, but also to explore if
the biotin-conjugated capture antibody could be coated onto a
biotinylated capillary surface via multivalent streptavidin
(Fig. 3A).
Biotin coating was detected with both the photoreactive
biotin and with NHS-biotin. The maximal photoreactive biotin
coating was achieved after 20 minutes of irradiation (Fig. 3B).
However, the biotin levels achieved with NHS-biotin were sig-
nificantly higher than with photoreactive biotin, and when we
attempted to quantify biotin levels following NHS-biotin
coating using the 4 µg mL−1 streptavidin–enzyme conjugate,
the OPD substrate precipitated, preventing a direct quantitative
comparison of biotin levels between the two methods. NHS-
biotin levels were therefore quantified using a far lower con-
centration of SA-HRP (Fig. 3C). To determine the optimal con-
centration of APTES, a reduced concentration of the 0.04
µg mL−1 streptavidin–enzyme conjugate was used to quantify
biotin, and we found that the APTES treatment significantly
increased biotin levels that were dependent on the APTES con-
centration (Fig. 3C). No signal was observed at either concen-
tration of SA-HRP in control PVOH-coated strips treated identi-
cally but without either photoreactive biotin or APTES and
NHS biotin, indicating that the modified surfaces were not
non-specifically binding and that the signal observed reflected
the immobilisation of biotin.
PVOH modification with a range of alkoxysilanes including
APTES was previously studied for the production of nano-
structured crosslinked networks of solid supports for immuno-
assays,32 and our observation that APTES modified PVOH
coated onto FEP microchannels provides an excellent surface
for NHS-ester coupling warrants further research to better
understand the nature of this APTES/PVOH coating. For
example, the orientation of the antibody onto APTES functio-
nalised gold sensors was studied in detail.5 Likewise, APTES
modification has been previously shown to facilitate gluta-
raldehyde immobilisation of the antibody within glass micro-
capillaries, but we did not explore if the APTES coating of
PVOH could improve glutaraldehyde mediated immobilisation
due to the increased background observed previously with glu-
taraldehyde-treated PVOH.
We explored briefly if biotinylated capture mAb could be
indirectly immobilised to biotinylated PVOH via streptavidin,
as streptavidin is tetrameric giving a maximum valency of 4 to
biotin, allowing bridging between a biotinylated surface to a
biotinylated antibody. Firstly, we measured streptavidin
coating levels using biotinylated HRP and found around 2-fold
higher levels using APTES-coated PVOH reacted with NHS-
biotin, than with photoactivated biotin (Fig. 3D). The absence
Fig. 3 Indirect immobilisation of the capture antibody to biotin-conju-
gated PVOH coating via streptavidin. (A) Schematic illustrating the bio-
conjugation strategy for streptavidin and biotin immobilisation onto
PVOH-coated ﬂuoropolymer microcapillaries. (B) Eﬀect of the UV illumi-
nation time on photoactivated biotin levels detected using high concen-
trations of HRP–streptavidin (4 μg mL−1). (C) Eﬀect of APTES treatment
of PVOH-coated FEP microcapillaries on NHS-biotin levels detected
using low concentrations of streptavidin–HRP (0.04 μg mL−1). (D)
PVOH-coated ﬂuoropolymer MCF strips were biotin coated using either
photoactivated biotin or APTES plus NHS-biotin, and then incubated
with the indicated concentrations of streptavidin. Streptavidin levels
were then measured using biotin-HRP to determine the biotin-binding
density of the microcapillaries. (E) Biotinylated capture antibody was
immobilised onto streptavidin-coated microcapillaries and the density of
the capture antibody then evaluated using anti-mouse HRP, and com-
pared to levels achieved with the passively adsorbed capture antibody.
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of a signal with control samples without streptavidin indicated
that the signal was specific for captured streptavidin, rather
than the non-specific binding of biotinylated HRP. When the
biotinylated cTnI capture antibody was coated onto these two
streptavidin-treated biotin-coated surfaces, a significant level
of the capture antibody was detected on streptavidin coated
NHS-biotin/APTES-coated PVOH (Fig. 3E), although at lower
levels than with passively adsorbed capture antibody. In con-
trast, the capture antibody could not be detected with the
photoactivated biotin surfaces, presumably because of the
lower biotin levels (Fig. 3D). Again, control strips without the
biotinylated capture antibody showed no signal with anti-
mouse-HRP, confirming that the signal observed was specific
to the immobilised capture antibody. We suggest several limit-
ations to this indirect capture approach. Firstly, it is possible
that multiple biotin molecules on the PVOH coating were
saturating the streptavidin, preventing the capture of
additional biotin on the capture antibody. Secondly, it is poss-
ible that the streptavidin preparation used in this study is not
of suﬃcient purity and may not be uniformly tetrameric, redu-
cing the valency of biotin binding and limiting eﬀectiveness
for bridging.33 Therefore, although we found indirect immobil-
isation via streptavidin is feasible, this method prevents the
use of biotinylated detection antibodies for detection, and
given the low maximal capture antibody density achieved, a
full immunoassay was not attempted here with this method.
Eﬀective antibody immobilisation to PVOH-coated FEP
microcapillaries using a NHS-maleimide crosslinker
The biotin capture tests clearly indicated that an NHS-ester
linker is suﬃciently reactive to APTES-treated PVOH to allow
bioconjugation to PVOH-coated FEP microcapillaries. A broad
range of diﬀerent NHS-ester crosslinkers are commercially
available to link diﬀerent reactive groups to PVOH via NHS-
ester, and APTES is inexpensive for PVOH pre-treatment. We
therefore selected a NHS-ester plus maleimide bifunctional
crosslinker, SM-[PEG]24-maleimide (NHS-maleimide) to
immobilise an antibody to PVOH via partially reduced di-
sulfides (Fig. 4A).
For IL-1β capture mAb, high levels of the capture antibody
were successfully immobilised into PVOH-coated microcapil-
laries using this bioconjugation chemistry, with the capture
antibody density dependent on the concentration of PVOH
and the capture antibody (Fig. 4B). Without the capture anti-
body, no background signal was observed, confirming that the
anti-mouse-HRP was specifically measuring the antibody
immobilisation levels. Maximal capture antibody levels
approached that obtained by passive adsorption onto hydro-
phobic FEP, and when complete colorimetric IL-1β ELISA
assays were performed using assay conditions optimised for
passively adsorbed capture antibodies, MCF test strips with a
covalently immobilised antibody showed excellent analytical
performance with a reduced background compared to test
strips coated by passive adsorption (Fig. 4C). Note that again
assay data were presented using log–log axes to evaluate small
changes in the background across a wide dynamic range, but
although these plots can make the background signal appear
somewhat high, the overall background levels stayed well
below 0.1 absorbance units, falling closer to 0.01 absorbance
units when PVOH was coated at lower concentrations of
0.1–1 mg mL−1.
Interestingly, when the fluorescent substrate AttoPhos –
rather than colorimetric substrate OPD – was used, with the
alkaline phosphatase enzyme replacing the HRP enzyme, a
higher background was observed when the capture antibody
was covalently immobilised than with passive adsorption
(Fig. 4D). Although the background was higher with the co-
Fig. 4 Eﬀective IL-1β ELISA and capture antibody immobilisation in
ﬂuoropolymer microcapillaries using APTES treated PVOH and an NHS-
ester-maleimide crosslinker. (A) Schematic illustrating the immobilisation
strategy. (B) Capture antibody density was measured using anti-mouse
HRP following immobilisation via NHS-maleimide plus APTES onto
PVOH-coated FEP microcapillaries with varying PVOH and capture anti-
body concentration, and contrasted to passive adsorption. (C) Full colori-
metric and (D) ﬂuorimetric IL-1β sandwich ELISA performed in MCF
strips coated with 80 μg mL−1 capture antibody immobilised using the
same conjugation conditions as in (B). In all plots, each data point
represents the mean absorbance or ﬂuorescence intensity of 10 indivi-
dual capillaries, and error bars indicate 2 standard deviations. Note:
immunoassay data are presented on a log–log scale to allow visuali-
sation of the signal variation across a large dynamic range (C, D), in con-
trast to the measurement of the capture antibody density presented on
linear plots (B).
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valently immobilised capture antibody than with the adsorbed
antibody, the background was still relatively low, with the
overall analytical performance using a covalently immobilised
capture antibody and fluorescent enzyme detection was still
excellent, with a limit of detection of 6 pg mL−1 achieved. The
background might have been expected to be lower with alka-
line phosphatase than HRP, given the significantly
slower enzyme kinetics, but the fluorometric substrate is
detectable at lower concentrations than the colorimetric
product of OPD, compensating for the slower enzyme kinetics.
The diﬀerence between the two detection modes is therefore
believed to be caused by diﬀerences in the background
enzyme conjugate binding to the fluoropolymer capillary
surface coating process.
The steep response curves in Fig. 4 suggests the limit of
detection could be much lower, but to determine this further
experimental data points will be needed in the range of
protein below 10 pg mL−1 when the assay has been fully opti-
mised. Again, note that the use of the log–log plot of assay
data exaggerates the background; the background level
remained well below 0.2 normalised fluorescence units. These
assays were performed without protocol re-optimisation, and
these diﬀerences therefore illustrate clearly the need for proto-
col optimisation for each and every set of assay reagents. This
diﬀerence in the background between colorimetric/HRP detec-
tion and fluorescent/alkaline phosphatase detection highlights
the unpredictable impact of the antibody immobilisation
method on assay performance.
When cTnI assays were performed using the NHS-malei-
mide immobilisation method, the capture antibody density
was also dependent on the capture antibody and PVOH con-
centration. The highest level of the capture antibody again
failed to reach the maximal levels achieved with passive
adsorption (Fig. 5A) however this may not necessary reduce the
analytical performance, as previous reports have demonstrated
that covalent immobilisation strategies can avoid potential dis-
advantages of passive adsorption and give better control of the
antibody orientation.1–6 The maleimide active group can react
with primary amines as well as free thiols, and so we tested if
the reduction of disulfides on the capture mAb was necessary
for immobilisation. A higher capture mAb density was seen
with the reduced capture antibody indicating as expected that
the maleimide-activated surface was more reactive to reduced
disulfides than free amides (Fig. 5A). Full cTnI ELISA perform-
ance with NHS-maleimide covalently immobilised capture
mAb was adequate without further optimisation, demonstrat-
ing that functional cTnI capture antibody immobilisation is
feasible with this method (Fig. 5B). A similar analytical per-
formance was seen with PVOH at 1.0 or 0.1 mg L−1. Although
the activated maleimide group hydrolyses in water fairly
rapidly, we prevented the surface from binding non-specifically
after reaction with the capture antibody by extensive blocking
with a protein blocking solution. Furthermore, the recombi-
nant analyte was diluted in 3% w/v BSA prior to the prepa-
ration of standards in a protein containing blocking buﬀer to
ensure that the analyte would not non-specifically bind to the
treated surface. We found no evidence of residual non-specific
binding for example to the capture antibody or enzyme conju-
gate with this protocol.
Only low concentrations of PVOH were required to achieve
maximal levels of covalent antibody immobilisation, and inter-
estingly the level of the capture antibody detected with the
highest tested PVOH concentration (20 mg ml−1) appeared to
be significantly reduced compared to a lower PVOH concen-
Fig. 5 Eﬀective cTnI ELISA and capture antibody immobilisation inside
ﬂuoropolymer microcapillaries using APTES treated PVOH and an NHS-
ester-maleimide crosslinker. (A) cTnI capture antibody density was
measured using anti-mouse HRP following immobilisation via NHS-malei-
mide plus APTES onto PVOH-coated FEP microcapillaries with varying
PVOH and capture antibody concentration, and contrasted to passive
adsorption. (B) Full colorimetric cTnI sandwich ELISA performed using
80 μg mL−1 capture antibody immobilised using the same conditions as
in (A). Note: immunoassay data are presented on a log–log scale to
allow visualisation of signal variation across a large dynamic range (A), in
contrast to the measurement of the capture antibody density presented
on linear plots (B).
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tration of 0.1–1 mg ml−1 (Fig. 4B and 5A). However, further
investigation is needed to determine if the higher concen-
trations of PVOH simply inhibit the detection of capture mAb
by the anti-mouse-HRP used to measure capture mAb levels,
or alternatively if the conjugation eﬃciency is actually
reduced. PVOH has previously been identified as a potential
blocking agent for ELISA.34 When tested as a blocking reagent
for FEP MCF immunoassays following passive capture anti-
body adsorption, PVOH was found to reduce the ELISA back-
ground at low concentrations, but can also inhibit a signal at
higher concentrations (Fig. S3†), possibly by hindering analyte
and reagent diﬀusion to the detection surface.
This bioconjugation method using the bifunctional NHS-
maleimide crosslinker to firstly react NHS-ester with APTES-
coated PVOH, and then react with free thiols on mildly
reduced capture mAb was clearly the most eﬀective and con-
trollable method of covalent capture antibody immobilisation
developed here, proved successful, with the capture antibody
density approaching that achieved with passive adsorption and
the full IL-1β assay showing limits of detection ranging from
10–23 pg mL−1 using colorimetric detection without further
optimisation (Fig. 4C), close to the maximal sensitivity of 7.4
pg ml−1 previously achieved using an assay protocol fully opti-
mised for a passively adsorbed capture antibody.19 The
dynamic range of these non-optimised assays using the co-
valently immobilised capture antibody was not studied in
detail, but an increase in the signal was still seen when the
analyte concentration was increased from 1 to 10 ng mL−1
with a colorimetric substrate and from 3 to 10 ng mL−1 with a
fluorimetric substrate. This indicates that the indirect immo-
bilisation using PVOH coating does not reduce the potential
assay dynamic range, and suggests that measurement over a
100 to 1000-fold dynamic range may well be feasible with fully
optimised assay conditions.
In the current study, reagent concentrations and assay proto-
cols optimised for maximal assay performance with a pas-
sively adsorbed capture antibody were used, and although the
covalently immobilised capture antibody did not immediately
improve the analytical sensitivity or quantitation over that
achieved by passive adsorption, we have not yet further opti-
mised assay protocols or reagent concentrations for the co-
valently immobilised antibody. For example, for any specific
diagnostic application, further optimisation of key parameters
such as concentrations of the immobilised capture antibody
and detection reagents, and screening of the blocking reagents
and wash conditions are typically required to achieve a clini-
cally appropriate sensitivity in biologically relevant samples.
Our previous study found that cytokine immunoassays per-
formed using a directly adsorbed capture antibody showed a
small impact of matrix eﬀects when blood or serum samples
were tested.19 The scope of the present study was to establish
the feasibility of published and novel immobilisation methodo-
logies for fluoropolymer devices, rather than to optimise
specific clinical diagnostic assays. Now that these new
methods for the covalent immobilisation of the functional
capture antibody within fluoropolymer devices have been
identified, further optimisation of all assay conditions is now
justified to determine the maximum analytical performance
that can be achieved using the covalent immobilisation
method. Alternative modified immobilisation strategies that
orient the capture antibody by selectively binding the Fc
region may also prove more eﬀective, such as immobilisation
via antibody-binding proteins such as protein G.35
Conclusions
This study showed for the first time that the covalent immobil-
isation of capture antibodies in fluoropolymer microfluidic
devices is feasible for quantitative, sensitive and rapid minia-
turised ELISA. Inert Teflon®-FEP microcapillaries can be func-
tionalised by permanently coating with high-molecular weight
PVOH, oﬀering a surface for the coupling of antibodies by a
range of chemistries. A novel bioconjugation strategy using a
bi-functional crosslinker and APTES-coated PVOH was devel-
oped that yielded a high density of functional capture antibody
without increasing the background binding that can strongly
limit the performance of immunoassays. Although glutaralde-
hyde could be used to immobilise the capture antibody onto a
PVOH layer and perform quantitative BNP assays, other
immunoassays showed a high background with this method
likely caused by the strong non-specific binding of the detec-
tion antibody to the glutaraldehyde coated PVOH layer. To
overcome these limitations, a novel and improved immobilis-
ation method utilised the bifunctional NHS-ester-maleimide
crosslinker to couple reduced disulfides in the antibody onto
an APTES-treated PVOH layer. This achieved a high capture
antibody density without increasing the assay background.
Using this method, a quantitative sandwich immunoassay for
IL-1β was demonstrated with a limit of detection of 6 pg mL−1
(i.e. 3.4 × 10−13 molar or 340 fM), which is at least as good
without any optimisation as the limit of detection previously
published with a fully optimised protocol and using passive
adsorption of the capture antibody. As well as demonstrating
the feasibility of the novel covalent antibody immobilisation
methods, we also report here for the first time a microfluidic
fluorescence enzyme IL-1β assay using an alkaline phospha-
tase substrate. Overall, this proof-of-concept study provides
simple and eﬀective methods for the derivatisation of inert
and hydrophobic fluoropolymer microfluidic devices with bio-
molecules, and justifies further research to develop the next
generation of fluoropolymer microfluidic devices.
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